S. Glossop

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

A. Rabow, D. M. Andrews, G. Walker, 2015, Journal of medicinal chemistry.

Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.

A. Lau, B. Barlaam, S. Degorce, 2016, Journal of medicinal chemistry.

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

C. A. Roberts, A. Rabow, M. Waring, 2016, Journal of medicinal chemistry.

A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase.

G. Smith, S. Glossop, G. R. Brown, 2000, Journal of medicinal chemistry.

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.

A. Ferguson, L. Drew, W. Shao, 2020, Journal of medicinal chemistry.

Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.

Allan Wu, Edward Hennessy, Jon Read, 2013, Journal of medicinal chemistry.

Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor.

G. Lamont, D. Buttar, S. Glossop, 2012, Bioorganic & medicinal chemistry letters.

Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: optimization from lipid profiles.

G. Smith, S. Glossop, G. R. Brown, 1999, Journal of medicinal chemistry.